CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons.
Rasmussen
K
K
Lilly Research Laboratories, Eli Lilly & Co., Lilly Corporate Center, Indianapolis, Indiana 46285.
D000818:Animals; D001007:Anxiety / Q000503:physiopathology*; D001921:Brain / Q000187:drug effects / Q000502:physiology / Q000503:physiopathology*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D011720:Pyrazoles / Q000378:metabolism / Q000494:pharmacology*; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D012559:Schizophrenia / Q000503:physiopathology*
D011720:Pyrazoles; D011949:Receptors, Cholecystokinin; C074681:1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone; D002766:Cholecystokinin; D006220:Haloperidol; D004298:Dopamine